Bastian Moritz B, Burgard Caroline, Blickle Arne, Speicher Tilman, Ezziddin Samer, Rosar Florian
Department of Nuclear Medicine, Saarland University, 66421 Homburg, Germany.
Diagnostics (Basel). 2024 Oct 18;14(20):2321. doi: 10.3390/diagnostics14202321.
We report a case of a 79-year-old male patient with a history of radical prostatectomy for prostate cancer. The patient presented with biochemical reoccurrence; however, previous conventional PSMA PET/CT using [F]PSMA-1007 showed two indetermined findings with low uptake in the right iliac lymph nodes. Further MRI evaluation provided no additional information. A recently introduced PSMA tracer, [Zr]Zr-PSMA-617 (half-life: 3.3 days), was administered in an attempt to confirm the diagnosis and aid in potential radiation planning. [Zr]Zr-PSMA-617 PET/CT clearly revealed the previously indetermined right iliac lymph nodes as definitely metastatic and also identified additional lymph node metastases that were undetected in prior scans. This case highlights the potential superior sensitivity of [Zr]Zr-PSMA-617 PET/CT in detecting recurrent disease, especially in unclear settings of [F]PSMA-1007 PET/CT and demonstrates its potential for guiding targeted radiation therapy with curative intent.
我们报告一例79岁男性患者，有前列腺癌根治术病史。该患者出现生化复发；然而，之前使用[F]PSMA - 1007进行的传统PSMA PET/CT显示右侧髂淋巴结有两个摄取低的不确定结果。进一步的MRI评估未提供更多信息。为了确诊并辅助潜在的放射治疗计划，使用了一种最近引入的PSMA示踪剂[Zr]Zr - PSMA - 617（半衰期：3.3天）。[Zr]Zr - PSMA - 617 PET/CT清楚地显示之前不确定的右侧髂淋巴结确实已转移，还发现了之前扫描未检测到的其他淋巴结转移灶。该病例突出了[Zr]Zr - PSMA - 617 PET/CT在检测复发性疾病方面潜在的更高敏感性，尤其是在[F]PSMA - 1007 PET/CT结果不明确的情况下，并证明了其在指导有治愈意图的靶向放射治疗方面的潜力。
